AI brief of an SEC Form 8-K · Healthpeak Properties (DOC)

Healthpeak Properties lowers 2025 EPS and Nareit FFO guidance after second-quarter results

Mixed Impact 4 of 5 guidance Written later

Healthpeak reported second-quarter 2025 diluted net income of $0.05 per share, down from $0.21 a year earlier, while Nareit FFO was $0.43 per share versus $0.44 and FFO as Adjusted and AFFO rose to $0.46 and $0.44 per share. The company cut its full-year 2025 diluted earnings per share guidance to $0.25 to $0.31 from $0.30 to $0.36 and Nareit FFO guidance to $1.78 to $1.84 from $1.81 to $1.87, while reaffirming its FFO as Adjusted guidance of $1.81 to $1.87 per share.

Key points

  • Q2 2025 diluted net income was $0.05 per share versus $0.21 in Q2 2024.
  • Q2 2025 Nareit FFO was $0.43 per share versus $0.44; FFO as Adjusted was $0.46 versus $0.45; AFFO was $0.44 versus $0.40.
  • 2025 diluted EPS guidance lowered to $0.25 to $0.31 from $0.30 to $0.36; Nareit FFO guidance lowered to $1.78 to $1.84 from $1.81 to $1.87.
  • Monthly dividend of $0.10167 per share declared for July, August and September 2025, totaling $0.305 for the third quarter; approximately $2.3 billion of liquidity as of July 24, 2025.

The filing

CompanyHealthpeak Properties (DOC)
Form8-K, current report
Filed with the SECJul 24, 2025, 4:17 PM ET
Accession number0001628280-25-035929

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 24, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.